Elite in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Stephen M. Ansell

Hematology
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
32 Years of Experience
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Ansell is a Hematologist in Rochester, Minnesota. Dr. Ansell has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

His clinical research consists of co-authoring 468 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 54 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Specialties
Hematology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, Varlilumab
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug, Other, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin, Etoposide, Lenalidomide, Prednisone, Vincristine
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 1/Phase 2
Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: April 21, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
Enrollment Status: Completed
Publish Date: May 16, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 13 Less Clinical Trials

468 Total Publications

Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
Journal: American journal of hematology
Published: June 20, 2025
Similar Doctors
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Grzegorz Nowakowski
Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Grzegorz Nowakowski
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Grzegorz Nowakowski is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Nowakowski is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Thomas M. Habermann
Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Thomas M. Habermann
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Habermann is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Habermann is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Habermann is currently accepting new patients.

Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Thomas E. Witzig
Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Thomas E. Witzig
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Witzig is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Witzig is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Witzig is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ansell's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 15 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile